These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37899968)

  • 1. A mechanistic assessment of the nature of pharmacodynamic drug-drug interaction in vivo and in vitro.
    Bisaso KR; Mukonzo JK; Ette EI
    In Silico Pharmacol; 2023; 11(1):31. PubMed ID: 37899968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
    Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R
    BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo.
    Jonker DM; Visser SA; van der Graaf PH; Voskuyl RA; Danhof M
    Pharmacol Ther; 2005 Apr; 106(1):1-18. PubMed ID: 15781119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.
    Terranova N; Germani M; Del Bene F; Magni P
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):471-82. PubMed ID: 23812004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
    Meng J; Dai B; Fang B; Bekele BN; Bornmann WG; Sun D; Peng Z; Herbst RS; Papadimitrakopoulou V; Minna JD; Peyton M; Roth JA
    PLoS One; 2010 Nov; 5(11):e14124. PubMed ID: 21124782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbubble therapy enhances anti-tumor properties of cisplatin and cetuximab in vitro and in vivo.
    Heath CH; Sorace A; Knowles J; Rosenthal E; Hoyt K
    Otolaryngol Head Neck Surg; 2012 Jun; 146(6):938-45. PubMed ID: 22323435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo.
    Li R; Wang Q; Zhao Y; Zhu Y; Wang X
    Mol Biol Rep; 2024 Mar; 51(1):455. PubMed ID: 38536540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
    Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
    Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
    Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
    J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
    Tonra JR; Deevi DS; Corcoran E; Li H; Wang S; Carrick FE; Hicklin DJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2197-207. PubMed ID: 16609035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures.
    Allen-Coyle TJ; Niu J; Welsch E; Conlon NT; Garner W; Clynes M; O'Sullivan F; Straubinger RM; Mager DE; Roche S
    AAPS J; 2022 Oct; 24(6):108. PubMed ID: 36229752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
    Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
    Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.
    Adjei AA; Davis JN; Bruzek LM; Erlichman C; Kaufmann SH
    Clin Cancer Res; 2001 May; 7(5):1438-45. PubMed ID: 11350915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line.
    Formelli F; Cleris L
    Eur J Cancer; 2000 Dec; 36(18):2411-9. PubMed ID: 11094318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro.
    Jekunen AP; Christen RD; Shalinsky DR; Howell SB
    Br J Cancer; 1994 Feb; 69(2):299-306. PubMed ID: 7905279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
    Smalley KS; Eisen TG
    Int J Cancer; 2003 Jun; 105(2):165-75. PubMed ID: 12673674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma.
    Kwon J; Yoon HJ; Kim JH; Lee TS; Song IH; Lee HW; Kang MC; Park JH
    Oncol Rep; 2014 Sep; 32(3):1188-92. PubMed ID: 24993015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
    Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.